# \[e-drug\] ADRs and cox 2 inhibitors (continued) **URL:** \ **Category:** e-drug\ **Created:** [August 29, 2000, 12:56am UTC](https://talk.edrugplus.org/t/e-drug-adrs-and-cox-2-inhibitors-continued/9022 "2000-08-29T00:56:12Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![BUKO\_Pharma-Kampagne](https://avatars.discourse-cdn.com/v4/letter/b/4bbf92/32.png) [@BUKO\_Pharma-Kampagne](https://talk.edrugplus.org/u/BUKO_Pharma-Kampagne)\ **Post date:** [August 29, 2000, 12:56am UTC](https://talk.edrugplus.org/t/e-drug-adrs-and-cox-2-inhibitors-continued/9022/1 "2000-08-29T00:56:12Z")
E-drug: ADRs and cox 2 inhibitors (continued) --------------------------------------------- Celecoxib (CELEBREX) is a sulfonamide derivative. Sulfonamides are well known to cause (allergic) thrombocytopenia and may present as SCHONLEIN HENOCH syndrome in children. Therefore, this should be considered in the case reported by Jody Dalmacion from the Philippines, especially if there were preceding expositions to sulfonamides. Furthermore, all NSAIDs occasionally cause damage of the bone marrow including thrombocytopenia. However, the apparent acute onset argues against a toxic and for a immune allergic event. Gastro-intestinal bleedings are not rare events with cox-2-inhibitors, since there is only a reduction of serious GI events (bleeding, perforation, ulcers) from 1.8 to 1.3 events per 100 treatment years. You have to treat 200 patients for 1 year to prevent 1 ulcer, at about 200.000 US$ treatment costs. Healing such an event in the hospital only cost 2,000 US$. That is the price of innovations: 198.000 US$ more per ulcer treatment. Regards, Peter Prof.Dr. Peter S. Sch�nh�fer Institute of Clinical Pharmacology Central Hospital St.J�rgen Str. D-28209 Bremen, Germany Klin.Pharm@ZKHSTJUERGEN.BREMEN.DE scientific adviser of BUKO Pharma-Kampagne August-Bebel-Str. 62 33602 Bielefeld Germany bukopharma@compuserve.com BUKO is a NGO in Germany doing public awareness raising work on drugs in developing countries and is lobbying for rational drug policies worldwide. -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.